A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients, \>=18 years of age;
rheumatoid arthritis of \>=6 months duration diagnosed according to the revised 1987 ACR criteria;
DAS28 of \>3.2;
At screening either ESR \>=28 mm/h or CRP \>=1 mg/dL;
Having received permitted DMARDs, 1 or more; current DMARD therapy must have been at a stable dose for at least 8 weeks prior to baseline.
You may not be if
major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following screening;
functional class IV as identified by the ACR classification of functional status in RA;
rheumatoid autoimmune disease other than RA;
prior history of or current inflammatory joint disease other than RA.
Clareo Health | A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.
